Analyst Price Target is $7.33
▲ +344.44% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Gain Therapeutics in the last 3 months. The average price target is $7.33, with a high forecast of $8.00 and a low forecast of $6.00. The average price target represents a 344.44% upside from the last price of $1.65.
Current Consensus is
Buy
The current consensus among 3 investment analysts is to buy stock in Gain Therapeutics. This rating has held steady since July 2023, when it changed from a Moderate Buy consensus rating.
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.
Read More
